Zocto News
News

Fortis Healthcare Considers Supreme Court Appeal in Daiichi Sankyo Case

September 2, 2026
Fortis Healthcare Considers Supreme Court Appeal in Daiichi Sankyo Case
6 views
AI Summary

Fortis Healthcare may challenge a Delhi HC ruling requiring a forensic audit, potentially escalating a legal battle with Daiichi Sankyo.

Fortis Healthcare is contemplating an appeal to the Supreme Court following a recent ruling by the Delhi High Court concerning arbitration with Daiichi Sankyo. The court's decision, issued on Monday, mandates a forensic audit of Fortis’ transactions, significantly impacting the company by introducing a potential contingent liability.

Delhi High Court's Ruling

The Delhi High Court, in a detailed 213-page judgment, ordered a comprehensive forensic examination of Fortis Healthcare’s financial dealings. This audit covers transactions from the era of the Singh brothers' management to the period when IHH Healthcare assumed control. Justice Subramonium Prasad’s ruling suggests that any parties found violating court orders or obstructing the decree's execution could face legal consequences.

The judgment explicitly states that the court retains the authority to reverse transactions if the forensic audit uncovers participation by banks or financial institutions in activities that contravene judicial orders. This aspect of the ruling has sparked concerns about direct financial repercussions for Fortis, including the possibility of compensation to Daiichi Sankyo.

Potential Supreme Court Appeal

Given the gravity of the ruling, Fortis Healthcare is reportedly considering taking the matter to the Supreme Court. Legal experts suggest that the implications of the high court's decision could compel the company to seek higher judicial intervention. The ruling also scrutinizes the acquisition of controlling interest by IHH and questions the roles of involved parties.

Senior advocate Arvind Nigam and advocate Giriraj Subramanium represented Daiichi Sankyo in court. The high court emphasized that Fortis, despite its change in management, cannot claim ignorance of past managerial misconduct.

Background and Implications

The legal dispute stems from Daiichi Sankyo’s acquisition of a controlling stake in Ranbaxy Laboratories, previously owned by the Singh brothers. Allegations of fraud during this transaction have led to prolonged legal battles. The current ruling intensifies the situation by potentially holding Fortis accountable for past misdeeds.

As Fortis Healthcare evaluates its legal strategy, the outcome of this case could set significant precedents in corporate governance and accountability. The healthcare giant’s decision to approach the Supreme Court will likely be influenced by the audit's findings and the potential financial obligations imposed by the high court's order.

6 views